Shots: The study involves assessing of JHL1266 vs Prolia sourced from the EU and the US in healthy human subjects evaluating its PK, PD, and immunogenicity The JHL1266 is proved to be a milestone and an initiative in bringing safe, effective, and high-quality biologics JHL1266 is a mAb targeting RANKL works by inhibition of developed […]Read More
Shots: :Stosohth:ththShots: The company reported the dosing of a first healthy volunteer in a P-I study of TD-0903 and anticipates that TD-0903 has the potential to inhibit the cytokine storm associated with ALI and prevent progression to ARDS Earlier, Theravance has received approval to initiate the P-I study for assessing safety, tolerability and pharmacokinetics of […]Read More
![Daiichi Reports Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in P-I study for HER2 Low Expressing Metastatic Breast Cancer](https://pharmashots.com/wp-content/uploads/2018/12/Daiichi.jpg)
Shots: The P-I study involved assessing of [Fam-] trastuzumab deruxtecan (5.4, 6.4 mg/kg) in 46 patients with heavily pretreated HER2 low expressing metastatic breast cancer P-I study results: ORR (44.2 %, 47.4%); disease control rate (79.1%, 81.6%); mDOR (9.4mos., 11.0 mos.); mPFS (7.6 mos., 7.9 mos.) [Fam-] Trastuzumab deruxtecan (DS-8201) is a HER2 targeting antibody […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
